. "Appendix E: The Pathway from Idea to Regulatory Approval: Examples for Drug Development." Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: The National Academies Press, 2009.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Conflict of Interest in Medical Research, Education, and Practice
delivery modes, they must meet the same standards as the Phase III trials conducted for initial approval.
Baru, J. S., D. A. Bloom, K. Muraszko, and C. E. Koop. 2001. John Holter’s shunt. Journalof the American College of Surgeons 192(1):79-85.
Borie, D. C., J. J. O’Shea, and P. S. Changelian. 2004. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends in Molecular Medicine 10(11):532-541.
Changelian, P. S., D. Moshinsky, C. F. Kuhn, M. E. Flanagan, M. J. Munchhof, T. M. Harris, J. L. Doty, et al. 2008. The specificity of JAK3 kinase inhibitors. Blood 111(4):2155-2157.
IOM (Institute of Medicine). 2009. Breakthrough Business Models: Drug Development forRare and Neglected Diseases and Individualized Therapies. Washington, DC: The National Academies Press.
Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298(5600):1912-1934.
Russell, S. M., N. Tayebi, H. Nakajima, M. C. Riedy, J. L. Roberts, M. J. Aman, T. S. Migone, et al. 1995. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270(5237):797-800.
Stanczyk, J., C. Ospelt, and S. Gay. 2008. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Current Opinion in Rheumatology 20(3):257-262.